From the Guidelines
The number of cycles for Taxane, Carboplatin, Trastuzumab (Herceptin), and Pertuzumab (Perjeta) (TCHP) is 6 cycles.
Treatment Regimen
- The TCHP regimen is a standard treatment for HER2-positive breast cancer, particularly for patients at higher risk for cardiotoxicity 1.
- The regimen typically consists of:
- Docetaxel (Taxane)
- Carboplatin
- Trastuzumab (Herceptin)
- Pertuzumab (Perjeta)
- The 6-cycle regimen is supported by studies such as the BCIRG 006 study, which demonstrated improved disease-free survival and overall survival with the TCHP regimen compared to other treatment regimens 1.
Rationale
- The use of TCHP is recommended for patients with HER2-positive breast cancer, particularly those with high-risk disease or those who are at increased risk for cardiotoxicity 1.
- The regimen has been shown to be effective in reducing the risk of recurrence and improving overall survival in patients with HER2-positive breast cancer 1.
Clinical Considerations
- The TCHP regimen should be administered with caution in patients with pre-existing cardiac conditions or those who are at increased risk for cardiotoxicity 1.
- Regular monitoring of cardiac function is recommended during treatment with TCHP 1.
From the Research
Number of Cycles for TCHP
- The number of cycles for Taxane, Carboplatin, Trastuzumab (Herceptin), and Pertuzumab (Perjeta) (TCHP) is typically 6 cycles, as seen in several studies 2, 3, 4.
- A study comparing TCbHP and THP regimens found that 6 cycles of TCbHP resulted in a higher pathological complete response (pCR) rate compared to 4 cycles of THP 3.
- Another study using a triweekly regimen of docetaxel, carboplatin, and trastuzumab also consisted of 6 courses 4.
- However, it's worth noting that some patients may not be able to complete the full 6 cycles due to adverse events, as seen in a study where 17 out of 50 patients had their treatment delayed or discontinued 4.
Efficacy and Safety of TCHP
- The TCHP regimen has been shown to be effective in treating HER2-positive breast cancer, with pCR rates ranging from 52% to 66% 3, 4.
- However, the regimen is also associated with a higher incidence of adverse events, including neutropenia, anemia, and thrombocytopenia 2, 3, 4.
- The safety and efficacy of TCHP may vary depending on the patient population and specific treatment regimen, highlighting the need for individualized treatment plans 3, 5.